Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Challenge To “Authorized” Generics May Shift To Antitrust Arguments

Executive Summary

Mylan could turn to antitrust laws as an avenue for renewing a court challenge against "authorized" generics after dropping its lawsuit against FDA

You may also be interested in...



Duragesic Competition Could Add To Mylan’s “Authorized” Generics Fight

The anticipated launch of an "authorized" generic of J&J's Duragesic could give Mylan further ammunition in its ongoing fight against such products

Duragesic Competition Could Add To Mylan’s “Authorized” Generics Fight

The anticipated launch of an "authorized" generic of J&J's Duragesic could give Mylan further ammunition in its ongoing fight against such products

“Authorized” Generics Are “Legitimate Business Strategy,” Pfizer Says

Pfizer views "authorized" generics as a sound business strategy following a drug's patent expiration, Senior Corporate Counsel Jeffrey Chasnow said during a Drug & Device Dialogue audio conference Oct. 7

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel